Diabetic Macular Edema Treatment Market

A 2014 survey by the World Health Organization states that globally, around 422 million people suffer from diabetes, and approximately 2.6 percent of global blindness is due to diabetic retinopathy. The American Academy of Ophthalmology has stated that the incidence rate of diabetic macular edema in a span of 10 years is 20% in younger patients and 40% in older patients. Currently, combined therapy of photocoagulation laser therapy and anti-VEGF drugs is employed to achieve improved vision and avoid blindness. The drugs in phase III clinical trials, such as concept, fenofibrate, ranibizumab, and aflibercept intravitreal injection, are tested for better drug efficacy.

The therapy segment for the diabetic macular edema treatment market majorly comprises drugs and surgery. The drugs are further sub-segmented as anti-VEGF, corticosteroids, and other drugs (triamcinolone acetonide and bevacizumab). The anti-VEGF treatments adopted are ranibizumab and aflibercept. Corticosteroids include dexamethasone and fluocinolone acetonide. The surgery segment consists of photocoagulation laser therapy and intravitreal implants. In order to understand the current trend existing in the market, the data forecast and market estimation for the treatment segment are given in the scope of the report.

A brief description of the treatment regimen adopted across five major geographical regions is covered in the geography segment, which is as follows:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Russia
  • Rest of Europe
• Asia-Pacific
  • India
  • China
  • Japan
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

The market size estimation and the data forecasting are given for the geographical regions, and the cross-country sectional is given for the treatment segment.

The competitive landscape is an assessment tool that highlights the performance of the fundamental players currently engaged in the diabetic macular edema treatment market. The parameters employed are geographical presence, product portfolio, and inception. Company profiles give a brief update regarding the latest technological advancements in the photocoagulation laser therapy market and effective collaboration among niche players. The fundamental players in the diabetic macular edema treatment market are Allergan, Inc., Quantel-Medical, Alimera Sciences, Bausch and Lomb Incorporated, Carl Zeiss Meditec AG, Ellex, Genetech, Inc., IRIDEX Corporation, LUMENIS, Novartis AG, and Regeneron Pharmaceuticals, Inc.

Based on treatment, the diabetic macular edema treatment market is categorized into:

By Drugs

• Anti-VEGF
• Ranibizumab
• Aflibercept
• Corticosteroids
• Fluocinolone Acetonide
• Dexamethasone
• Others (triamcinolone acetonide, bevacizumab)

By Surgery

• Laser Photocoagulation Therapy
• Intravitreal Implants
• Pipeline Analysis

Drugs in Phase III

• Concept
• Fenofibrate
• 0.3 mg of ranibizumab intravitreal injection
• Aflibercept 2 mg
• Tabular Representation of Phase II and I Drugs

Diabetic macular edema is a complication seen in patients suffering from diabetic retinopathy in which the blood vessels of the macula region of the retina are damaged and allow the fluid to escape. It is prevalent in two forms: focal diabetic macular edema, which employs surgical treatment options, and diffuse macular edema, which is treated with drug therapy. Photocoagulation laser therapy is a standard treatment protocol for patients who have blurred or double vision.

The yellow-patterned 577 nm micropulse laser is preferred to the conventional green-patterned 532 nm laser due to less thermal absorption by the xanthophyll pigments. Since 2005, the anti-VEGF drug treatment has been considered the first line of treatment for diabetic macular edema, as it inhibits various isoforms of VEGF, thus enhancing vision and preventing blindness. Intravitreal implants will be the trendsetter during the forecast duration of 2015–2025; Retisert, Illuvien, and Ozurdex will provide high drug efficacy and safety. The prominent players in the diabetic macular edema treatment market are Allergan, Inc., Alimera Sciences, Bausch and Lomb Incorporated, Carl Zeiss Meditec AG, Ellex, Genetech, Inc., IRIDEX Corporation, LUMENIS, Novartis AG, Quantel-Medical, and Regeneron Pharmaceuticals, Inc.

As per the research findings of the Centers for Disease Control and Prevention (2015), there were around 4.2 million people suffering from diabetic retinopathy, with 655,000 of them suffering from diabetic retinopathy. The increasing number of U.S. citizens being diagnosed with type 2 diabetes and the recent USFDA approval of intravitreal implants such as Iluvien, Eylea, and Ozurdex will contribute to the growth of the North American diabetic macular edema treatment market.

The Western European region shows remarkable growth in the diabetic macular edema treatment market due to the presence of cardinal players and prolific investment in the research and development segment to develop intravitreal implants. Asia-Pacific reflects balanced growth as a result of the competitive market created by the global and domestic manufacturers of photocoagulation lasers. In addition, the supportive regulatory environment for drug therapies and intravitreal implants has a positive impact on the Asia-Pacific market. A proactive role played by government healthcare agencies to promote eye care and increase awareness of eyesight through campaigns conducted by major players will thrust the diabetic macular edema treatment market into growth in the Middle East and Latin America.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Diabetic Macular Edema Treatment Market Portraiture
2.1.1. Global Diabetic Macular Edema Treatment Market, by Treatment, 2016 (Value %)
2.1.2. Global Diabetic Macular Edema Treatment Market, by Geography, 2016 (Value %)

Chapter 3. Diabetic Macular Edema Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global Diabetic Macular Edema Treatment Market, 2015-2025 (US$ Mn)
3.7. Competitive Landscape: Global Diabetic Macular Edema Treatment Market, by Key Players, 2015-2025 (US$ Mn)

Chapter 4. Global Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Competitive Analysis: Global Diabetic Macular Edema Treatment Market, by Treatment, 2016 Vs. 2025 (Value %)
4.3. By Drugs
4.3.1. Anti-VEGF
4.3.1.1. Ranibizumab
4.3.1.2. Aflibercept
4.3.2. Corticosteroids
4.3.2.1. Fluocinolone Acetonide
4.3.2.2. Dexamethasone
4.3.3. Others (Triamcinolone Acetonide, Bevacizumab)
4.4. By Surgery
4.4.1. Photocoagulation Laser Therapy
4.4.2. Intravitreal Implants
4.5. Pipeline Analysis
4.5.1. Phase III Drugs
4.5.1.1. Conbercept
4.5.1.2. Pemofibrate
4.5.1.3. O.3mg Ranibizumab Intravitreal Injection
4.5.1.4. 2mg Aflibercept Intravitreal Injection
4.5.2. Tabular Representation of Phase II and I Drugs

Chapter 5. Global Diabetic Macular Edema Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Diabetic Macular Edema Treatment Market Analysis, 2015 – 2025
5.2.1. North America Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
5.2.2. North America Diabetic Macular Edema Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.2.2.1. U.S.
5.2.2.1.1. U.S. Diabetic Macular Edema Treatment Market, By Treatment, 2015-2025 (US$ Mn)
5.2.2.2. Canada
5.2.2.2.1. Canada Diabetic Macular Edema Treatment Market, By Treatment, 2015-2025 (US$ Mn)
5.3. Europe Diabetic Macular Edema Treatment Market Analysis, 2015 – 2025
5.3.1. Europe Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
5.3.2. Europe Diabetic Macular Edema Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.3.2.1. U.K.
5.3.2.1.1. U.K. Diabetic Macular Edema Treatment Market, By Treatment, 2015-2025 (US$ Mn)
5.3.2.2. Germany
5.3.2.2.1. Germany Diabetic Macular Edema Treatment Market, By Treatment, 2015-2025 (US$ Mn)
5.3.2.3. Rest of Europe
5.3.2.3.1. Rest Of Europe Diabetic Macular Edema Treatment Market, by Treatment, 2015-2025 (US$ Mn)
5.4. Asia Pacific Diabetic Macular Edema Treatment Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Diabetic Macular Edema Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.4.2.1. Japan
5.4.2.1.1. Japan Diabetic Macular Edema Treatment Market, by Treatment, 2015-2025 (US$ Mn)
5.4.2.2. China
5.4.2.2.1. China Diabetic Macular Edema Treatment Market, by Treatment, 2015-2025 (US$ Mn)
5.4.2.2.2. India Diabetic Macular Edema Treatment Market, by Treatment, 2015-2025 (US$ Mn)
5.4.2.3. Rest of Asia Pacific
5.4.2.3.1. Rest Of Asia Pacific Diabetic Macular Edema Treatment Market, by Treatment, 2015-2025 (US$ Mn)
5.5. Latin America Diabetic Macular Edema Treatment Market Analysis, 2015 – 2025
5.5.1. Latin America Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Diabetic Macular Edema Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.5.2.1. Brazil
5.5.2.1.1. Brazil Diabetic Macular Edema Treatment Market, by Treatment, 2015-2025 (US$ Mn)
5.5.2.2. Mexico
5.5.2.2.1. Mexico Diabetic Macular Edema Treatment Market, by Treatment, 2015-2025 (US$ Mn)
5.5.2.3. Rest of Latin America
5.5.2.3.1. Rest Of Latin America Diabetic Macular Edema Treatment Market, by Treatment, 2015-2025 (US$ Mn)
5.6. Middle East & Africa Diabetic Macular Edema Treatment Market Analysis, 2015 – 2025
5.6.1. Middle East and Africa Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
5.6.2. Middle East and Africa Diabetic Macular Edema Treatment Market, by Region, 2015 – 2025 (US$ Mn)
5.6.2.1. GCC
5.6.2.1.1. GCC Diabetic Macular Edema Treatment Market, by Treatment, 2015-2025 (US$ Mn)
5.6.2.2. Rest of Middle East and Africa
5.6.2.2.1. Rest Of Middle East and Africa Diabetic Macular Edema Treatment Market, by Treatment, 2015-2025 (US$ Mn)

Chapter 6. Company Profiles
6.1. Allergan, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Treatment Portfolio
6.1.4. Key Developments
6.2. Alimera Sciences
6.3. Bausch and Lomb Incorporated
6.4. Carl Zeiss Meditec AG
6.5. Ellex
6.6. Genetech, Inc.
6.7. IRIDEX Corporation
6.8. LUMENIS
6.9. Novartis AG
6.10. Quantel-Medical
6.11. Regeneron Pharmaceuticals, Inc.

List of Figures

FIG. 1 Diabetic Macular Edema Treatment: Market Segmentation
FIG. 2 Global Diabetic Macular Edema Treatment Market Share, by Treatment, 2016 (Value %)
FIG. 3 Global Diabetic Macular Edema Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Ranibizumab Market for Diabetic Macular Edema Treatment, 2015 – 2025 (US$ Mn)
FIG. 7 Global Aflibercept Market for Diabetic Macular Edema Treatment, 2015 – 2025 (US$ Mn)
FIG. 8 Global Fluocinolone Acetonide Market for Diabetic Macular Edema Treatment, 2015 – 2025 (US$ Mn)
FIG. 9 Global Other Drugs Market for Diabetic Macular Edema Treatment, 2015 – 2025 (US$ Mn)
FIG. 10 Global Photocoagulation Laser Therapy Market for Diabetic Macular Edema Treatment, 2015 – 2025 (US$ Mn)
FIG. 11 Global Intravitreal Implant Market for Diabetic Macular Edema Treatment, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Diabetic Macular Edema Treatment Market Portraiture
TABLE 2 Global Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 3 Global Drugs Market for Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 4 Global Anti-VEGF Drugs Market for Diabetic Macular Edema Treatment Market, 2015 – 2025 (US$ Mn)
TABLE 5 Global Corticosteroids Drugs Market for Diabetic Macular Edema Treatment Market, 2015 – 2025 (US$ Mn)
TABLE 6 Global Surgery Market for Diabetic Macular Edema Treatment Market, 2015 – 2025 (US$ Mn)
TABLE 7 Global Diabetic Macular Edema Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 8 North America Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 9 North America Diabetic Macular Edema Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 U.S. Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 11 Canada Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 12 Europe Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 13 Europe Diabetic Macular Edema Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 14 U.K. Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 15 Germany Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 16 Rest of Europe Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 17 Asia Pacific Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 18 Asia Pacific Diabetic Macular Edema Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 19 Japan Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 20 China Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 21 India Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 22 Rest of Asia Pacific Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 23 Latin America Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 24 Latin America Diabetic Macular Edema Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 25 Brazil Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 26 Mexico Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 27 Rest of Latin America Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 28 Middle East And Africa Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 29 Middle East And Africa Diabetic Macular Edema Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 30 GCC Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 31 Rest of Middle East and Africa Diabetic Macular Edema Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 32 Allergan, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 33 Alimera Sciences: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 34 Bausch and Lomb Incorporated: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 35 Carl Zeiss Meditec AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 36 Ellex: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 37 Genetech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 38 IRIDEX Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 39 LUMENIS: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 40 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 41 Quantel-Medical: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 42 Regeneron Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)